Biohaven Cash on Hand 2016-2022 | BHVN

Biohaven cash on hand from 2016 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Biohaven Annual Cash on Hand
(Millions of US $)
2021 $365
2020 $355
2019 $317
2018 $264
2017 $131
2016 $24
2015 $1
Biohaven Quarterly Cash on Hand
(Millions of US $)
2022-09-30 $51
2022-06-30 $553
2022-03-31 $602
2021-12-31 $76
2021-09-30 $520
2021-06-30 $366
2021-03-31 $566
2020-12-31 $355
2020-09-30 $546
2020-06-30 $261
2020-03-31 $428
2019-12-31
2019-09-30 $417
2019-06-30 $466
2019-03-31 $217
2018-12-31 $264
2018-09-30 $168
2018-06-30 $217
2018-03-31 $104
2017-12-31 $131
2017-09-30 $176
2017-06-30 $204
2017-03-31 $52
2016-12-31 $24
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.240B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00